On April 29, 2025, WeightWatchers announced a pharmacy integration with Eli Lilly and Company’s LillyDirect® pharmacy provider, Gifthealth. This partnership aims to streamline access to Lilly’s FDA-approved Zepbound® (tirzepatide) single-dose vials for WeightWatchers Clinic members.
The integration is designed to improve access and affordability, particularly for eligible self-pay patients who do not have insurance coverage for Zepbound. WeightWatchers reported that 33% of its Clinic members are now using Zepbound, and prescriptions for Zepbound vials have increased by over 100% in recent months.
Through this collaboration, WeightWatchers members will receive real-time prescription tracking directly within the WeightWatchers App, enhancing the fulfillment process from prescription to delivery. This initiative underscores WeightWatchers' commitment to providing evidence-based medications and holistic support to its growing number of members relying on GLP-1 treatments.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.